JOURNAL ARTICLE

Investigators at Tufts University Have Reported New Data on Psychosis (Nathan S. Kline: From the first treatments of psychosis and depression, a 70-year legacy of a pioneer of psychopharmacology).

  • Published In: Mental Health Weekly Digest, 2026. P. 1755 1 of 2

  • Database: Psychology Source 2 of 2

Abstract

This article focuses on the legacy of Nathan S. Kline, a pioneering clinician and researcher in psychopharmacology, particularly in the treatment of psychosis and depression. Kline was instrumental in introducing the first psychoactive substances into clinical practice, notably reserpine as a sedative and iproniazid, a monoamine oxidase inhibitor (MAOI) with antidepressant properties. His contributions extended beyond pharmacology to early health informatics and advocacy for expanding global mental health care, including in low- and middle-income countries. The research highlights the evolution of psychopharmacology from its early days to current efforts targeting novel synaptic signaling mechanisms. [Extracted from the article]

Additional Information

  • Source:Mental Health Weekly Digest. 2026/04, p1755
  • Document Type:Article
  • Subject Area:History
  • Publication Date:2026
  • ISSN:1543-6616
  • Accession Number:193054539
  • Copyright Statement:Copyright of Mental Health Weekly Digest is the property of NewsRx and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.